◀ Back to RAD51

MAP2K1 — RAD51

Text-mined interactions from Literome

Ko et al., Carcinogenesis 2008 (Carcinoma, Non-Small-Cell Lung...) : Enhancement of ERK1/2 signaling by constitutively active mitogen activated protein kinase kinase 1/2 ( MKK1/2-CA ) increased Rad51 protein levels and protein stability in gefitinib and cisplatin or MMC cotreated cells
Ko et al., Mol Cancer Res 2009 (Carcinoma, Non-Small-Cell Lung...) : Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells ... Blocking the activations of ERK1/2 and AKT by MKK1/2 inhibitor ( U0126 ) and phosphoinositide 3-kinase inhibitor ( wortmannin ) suppressed the expression of Rad51 and enhanced the erlotinib induced cell death in erlotinib-resistant cells
Niu et al., Mol Cell 2009 : Here, a combination of proteomic, biochemical, and genetic approaches has identified an additional role for Mek1 in inhibiting the activity of the Rad51 recombinase through phosphorylation of its binding partner, Rad54
Tsai et al., J Pharmacol Exp Ther 2010 (Carcinoma, Non-Small-Cell Lung) : Enforced expression of constitutively active MKK1/2 or AKT recovered cell viability and Rad51 protein levels that were decreased by the combination of erlotinib and gemcitabine
Ko et al., Toxicol Appl Pharmacol 2011 (Carcinoma, Non-Small-Cell Lung...) : Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2 mediated Rad51 expression in non-small cell lung cancer cells ... Enhancement of ERK1/2 activation by constitutively active MKK1/2 ( MKK1/2-CA ) increased Rad51 protein levels in curcumin and MMC co-treated human lung cells